Document is current

Article History

Received: 27 June 2024

Accepted: 19 November 2024

First Online: 24 January 2025

Declarations

:

: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). This article does not contain any studies with human participants or animals performed by any of the authors.

: The authors have completed the CARE reporting checklist.

: Written informed consent for publication of this case report was obtained. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

: AI reports consultancy for TG Therapeutics, Secura Bio; payment/honoraria from MJH Life Sciences, AstraZeneca, Seattle Genetics; owns stock or stock options from Merck, COTA Healthcare; and has other financial interests in COTA Healthcare, Genomic Testing Cooperative (Irvine, CA, USA). LL reports consultancy for ADC Therapeutics, Kite/Gilead, Beigene, Pharmacyclics, AbbVie, Genmab, SeaGen, Janssen, AstraZeneca, Eli Lily, Epizyme, TG Therapeutics, Merck; payment/honoraria from Kite/Gilead, Beigene, Pharmacyclics, AbbVie, Genmab, SeaGen, Janssen, AstraZeneca, Eli Lily, Epizyme, TG Therapeutics; and reports serving advisory role for ADC Therapeutics, Kite/Gilead, Beigene, Pharmacyclics, AbbVie, Genmab, Sea Gen, Janssen, AstraZeneca, Eli Lily, Epizyme, TG Therapeutics, Merck. TF reports consultancy for AbbVie, ADC Therapeutics, AstraZeneca, Daiichi Sankyo, Genmab, Karyopharm, KITE, MorphoSys, SecuraBIO; payment/honoraria from AbbVie, BMS/Celgene, Janssen, Pharmacyclics, Poteligeo, Seattle Genetics, Takeda; reports serving advisory role for AbbVie, ADC Therapeutics, AstraZeneca, Daiichi Sankyo, Genmab, Karyopharm, KITE, MorphoSys, SecuraBIO; and other financial interests in AstraZenca, BMS/Celgene, Corvus, Daiichi Sankyo, Eisai, Genmab, Juno, Kymera, MorphoSys, Portola, Seattle Genetics, and Tessa. AG reports grants or contracts from Acerta, Celgene, Constellation, Hackensack University Medical Center, Hoffman la Roche, Infinity Pharmaceuticals, Karyopharm, Kite, Pharmacyclics, AstraZeneca, BMS; consultancy for Acerta, Physician Education Resources, Xcenda, Novartis, Clinical Advances in Hematology/Oncology, Kite/Gilead, Michael J Hennessey, Inc, AbbVie, Pharmacyclics; payment/honoraria from Clinical Advances in Hematology & Oncology, Physicians Education Resource, OncLive Peer Exchange, Michael J Hennessey Associates, BMS, GCC Hematology Expert Forum, Xcenda; reports serving advisory for Vincerx Pharma, Janssen, Kite/Gilead, AbbVie, Pharmacyclics, BMS, AstraZeneca, Alloplex; leadership role at COTA Healthcare, Genomic Testing Cooperative, Kite/Gilead, Janssen, Acerta, AstraZeneca, Peer Review; owns stock or stock options in COTA Healthcare; and reports other financial interests in AstraZeneca, Hoffman la Roche. MA reports that work and owns stocks in Genomic Testing Cooperative (Irvine, CA, USA). The other authors have no conflicts of interest to declare.